ADAR1 Capital Management’s Moderna MRNA Stock Holding History

ADAR1 Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-9,000	Closed	-$374K	–	238
2024 Q4	$374K	Buy	+9,000	New	+$430K	0.07%	124

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ADAR1 Capital Management's MRNA Position: Q1 2025 in Review

ADAR1 Capital Management sold out of Moderna (MRNA) in Q1 2025, closing a stake of 9,000 shares — an estimated $374K sold.

ADAR1 Capital Management first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $374K in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

ADAR1 Capital Management reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
ADAR1 Capital Management sold 9,000 Moderna shares in Q1 2025, an estimated $374K.
ADAR1 Capital Management first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
ADAR1 Capital Management's Moderna position peaked at $374K in Q4 2024.
693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on ADAR1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.